Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

74.06 +0.59 (+0.81%)
Streaming Delayed Price Updated: 11:13 AM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
These Analysts Increase Their Forecasts On PTC Therapeutics ↗
 
Via Benzinga
News headline image
FDA Approval Sparks Bullish Momentum In PTC Therapeutics — Here’s What Happened ↗
The regulator approved Sephience for a broad range of PKU patients, including children as young as one month, based on Phase 3 data showing sustained reductions in phenylalanine levels. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock at a Fair Valuation ↗
PTC Therapeutics (PTCT) offers strong growth potential with solid financials and attractive valuation, making it a top pick for investors seeking affordable growth in biopharma. 
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation ↗
PTC THERAPEUTICS INC (NASDAQ:PTCT) offers strong growth potential with reasonable valuation, supported by solid financial health and profitability metrics. A biotech stock worth watching. 
Via Chartmill
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) – A Strong Growth Stock with Technical Breakout Potential ↗
PTC THERAPEUTICS INC (NASDAQ:PTCT) shows strong growth fundamentals and a promising technical breakout pattern, making it a stock to watch for growth investors. 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
Via ACCESS Newswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation ↗
PTC THERAPEUTICS (NASDAQ:PTCT) offers strong growth potential at a reasonable valuation, with solid profitability and financial health. A closer look at this biotech stock may be worthwhile for growth... 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) - A Biotech Stock With Strong Growth and Reasonable Valuation ↗
PTC THERAPEUTICS (NASDAQ:PTCT) offers strong growth potential with reasonable valuation, solid profitability, and financial health, making it an interesting stock for growth investors. 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
From Pomerantz LLP
Via GlobeNewswire
News headline image
This National Vision Holdings Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday ↗
 
Via Benzinga
News headline image
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday ↗
 
Via Benzinga
News headline image
PTC Therapeutics (PTCT) Q1 2025 Earnings Call ↗
Via The Motley Fool
News headline image
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? ↗
PTC518 showed reduced HTT protein and plasma NfL levels in Huntington's patients, with signals of clinical benefit across multiple functional scales. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Falls Over 2%; ISM Services PMI Rises In April ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.